GlassScriptPhysician profile
Marisa Pizzi
NPI 1447626858
$587.64
in general payments reported to CMS, 2019-2025
10 companies · $241 in 2025
The $241 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $42.42 · 2022: $29.76 · 2023: $114 · 2024: $161 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $515.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $118.71 | 2021-2025 | Bexsero, Penmenvy |
| Pfizer INC. | $118.65 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $80.00 | 2024-2025 | Gardasil 9, Vaxneuvance, M-M-R II |
| Ironshore Pharmaceuticals INC. | $61.58 | 2023-2024 | Jornay Pm |
| Seqirus USA INC | $49.17 | 2022-2025 | Flucelvax |
| Collegium Pharmaceutical, INC. | $42.59 | 2025 | Jornay Pm |
| Kaleo, INC. | $42.36 | 2023-2024 | Auvi-Q |
| Sanofi Pasteur INC. | $39.43 | 2023-2024 | |
| Alk-Abello, INC | $20.65 | 2025 | Neffy |
| Kowa Pharmaceuticals America, INC. | $14.50 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marisa Pizzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.